# MW151 and Whole-brain Radiotherapy in Patients With Intracranial Metastases

> **NCT05417282** · PHASE1 · COMPLETED · sponsor: **ImmunoChem Therapeutics, LLC** · enrollment: 27 (actual)

## Conditions studied

- Cognitive Dysfunction, Cognitive Disorder

## Interventions

- **DRUG:** MW151

## Key facts

- **NCT ID:** NCT05417282
- **Lead sponsor:** ImmunoChem Therapeutics, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-07-01
- **Primary completion:** 2025-07-31
- **Final completion:** 2025-07-31
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2025-10-15

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05417282

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05417282, "MW151 and Whole-brain Radiotherapy in Patients With Intracranial Metastases". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05417282. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*